A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Cannot have received: chemotherapy

Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug (Cohort A)

Cannot have received: radiation therapy

Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug (Cohort A)

Cannot have received: immune checkpoint inhibitor

Received immune checkpoint inhibitor or systemic immunosuppressive therapy was administered within 14 days prior to the first study (Cohort B and C)

Cannot have received: systemic immunosuppressive therapy

Received immune checkpoint inhibitor or systemic immunosuppressive therapy was administered within 14 days prior to the first study (Cohort B and C)

Cannot have received: traditional Chinese medicine with anticancer indication

traditional Chinese medicine with anticancer indication within 14 days prior to the first dose of study drug

Cannot have received: investigational drug or device

use of any investigational drug or device within 28 days prior to the first dose of study drug

Cannot have received: nectin-4 targeted ADC with MMAE payload

received treatment of nectin-4 targeted ADC with MMAE payload

Cannot have received: P-glycoprotein (P-gp) inducers/inhibitors

any P-glycoprotein (P-gp) inducers/inhibitors or strong CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug

Cannot have received: strong CYP3A4 inducers/inhibitors

any P-glycoprotein (P-gp) inducers/inhibitors or strong CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug

Cannot have received: major surgery

major surgery within 28 days prior to first dose of study drug

Cannot have received: live vaccines

any live vaccines within 28 days before first dose of study drug or during the study